Navigation Links
New hope for hepatitis C sufferers
Date:2/7/2008

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

The scientists, who are also attached to the Institute of Medical and Veterinary Science and Royal Adelaide Hospital, hope to identify antiviral proteins that can be used in the fight against hepatitis C.

Currently there is no effective vaccine and the existing treatment is expensive and often causes severe side effects. The success rate also varies between 50-80% so many sufferers cannot be helped by current approaches.

The funds, awarded by the National Health and Medical Research Council (NHMRC), are part of a larger $17.7 million joint program grant, tackling both HIV/AIDS and hepatitis C and involving nine scientists from across Australia.

Dr Beard said this was the first Australian program grant awarded to study both HIV/AIDS and HCV/hepatitis C.

The development of vaccines and better treatments for both these viruses are urgent global health priorities, Dr Beard said. This program brings together a team of researchers with skills in basic virology and immunology with experts who can translate laboratory findings into human clinical trials.

This latest grant is an adjunct to three NHMRC project grants awarded to Dr Beards team in the past two years specifically for hepatitis C research.

In 2006 the virologist was awarded more than $894,000 to investigate the link between alcohol and hepatitis C, and the basic mechanisms of liver disease.

In Australia, more than 264,000 people have been infected with the hepatitis C virus and there are approximately 10,000 new infections per year. A proportion of these are intravenous drug users, with alcohol playing a significant role in disease progression, Dr Beard said.

He said vaccines had been trialled for HIV, but with little success. There is antiretroviral treatment but this does not eradicate HIV, it only keeps it under control for a period of time. It is also very expensive and therefore not accessible on a global scale.

Dr Beard said the program would provide a pipeline to develop and test vaccines and novel treatments in a timely fashion.


'/>"/>

Contact: Michael Beard
michael.beard@adelaide.edu.au
61-883-035-522
University of Adelaide
Source:Eurekalert  

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Who will recover spontaneously from hepatitis C virus infection
3. Possible hepatitis C vaccine
4. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
5. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
6. New Swedish research hope for millions of sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope for hepatitis C sufferers
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: